An observational study in Rheumatoid Arthritis-Associated Interstitial Lung Disease, sponsored by Assiut University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Arthritis, Rheumatoid by Assiut University — 22 open to participants now, 22 under way, none of them phase 3. Arthritis, Rheumatoid · Assiut University.
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, this one is the 15th largest by enrollment of the 43 observational ones that give a count, is one of 6 that started in 2023, is one of 43 observational ones, and was the 28th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →22 of the 49 studies in Arthritis, Rheumatoid by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18–50
Assiut University
Ages 18–65
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 6 started in 2023.
This study's enrollment of 95 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 90 across the 6 interventional studies, 80 across the 43 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
9 of the studies in Arthritis, Rheumatoid by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07761767Assiut UniversitySelf-Care Education for Joint Stiffness and Functional Ability in Rheumatoid Arthritis | 2027-01-01 |
| NCT07129837Assiut UniversitySerum Anti-PCOLCE as Novel Diagnostic Biomarker in Rheumatoid Arthritis With Emphasis on Seronegative Patients. | 2027-03 |
| NCT07657156Assiut UniversityMusculoskeletal Ultrasound for Differentiating Rheumatoid and Gouty Arthritis | 2027-07 |
| NCT07105566Assiut UniversityTriosephosphate Isomerase Level in Relation to Rheumatoid Aerthritis Activity and Structural Damage | 2027-09 |
| NCT07810569Assiut UniversityOcular Surface Changes and Meibomian Gland Dysfunction in Rheumatologic Patients | 2027-10 |
Add all 9 to your calendar (.ics) → With an account.
Among the 49 studies in Arthritis, Rheumatoid by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptian Hospitals . Pumlonary involvement is common in rheumatoid arthritis (RA). Interstitial lung disease associated rheumatoid arthritis (ILD-RA) is responsible for significant morbidity and mortality .
Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that is found mainly on the surface of type II pneumocytes as well as in bronchiolar epithelial cells . It has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury .
Krebs von den Lungen-6 (KL6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. KL6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (IPF) . KL6 was found useful as well in predicting in-hospital mortality in patients with Acute exacerbation of interstitial lung disease (AE-ILD) . KL-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (CTD-ILD). It can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . Its value in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) has not yet been adequately investigated.
all patients have rheumatoid arthritis-associated interstitial lung disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010.
Inclusion Criteria:
Exclusion Criteria:
Rheumatoid Arthritis-associated Interstitial Lung Disease
Diagnostic Test: Krebs von den Lungen-6 (KL6)
Rheumatoid Arthritis without Interstitial Lung Disease
Diagnostic Test: Krebs von den Lungen-6 (KL6)
KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).
Also known as: Spirometry, HRCT Chest
KL-6
detect its serum level
Time frame: one day
Spirometry
FEV1, FVC, FVC/FEV1 will be measured.
Time frame: one day
HRCT chest
It will be will be assessed by the radiologist to determine pulmonary involvement.
Time frame: one day
Ran from May 2023 to primary completion in Apr 2024, 11 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Jan 2023 → May 2023, primary completion Dec 2023 → Apr 2024 and completion Dec 2023 → Apr 2024.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.